Search Results

In 2024, Signals ChemDraw, Signals Clinical and Signals Synergy launched. Read how Revvity Signals supports new modalities in drug discovery and research development.

Nexus 2021 Day Two Recap: Empowering Data-Driven Science with Flexible Informatics Day Two of Revvity Signal's Nexus 2021 Informatics Virtual User Conference delivered another engaging slate of presenters – from Merck KGaA, Birla Carbon and Givaudan to Bayer, Nimbus Therapeutics and Johnson & Johnson. If you’ve registered but missed a session (or even a day...

Revvity Signals was first-to-market with SaaS software and integrates AI to help empower scientists. Read our interview with David Gosalvez to learn the future vision of Revvity Signals.

Revvity introduces groundbreaking Phenologic.AI software at SLAS 2025, transforming cellular imaging workflows and showcasing innovative life sciences solutions for drug discovery and development.

Creating data is easy. The rapid analysis and use of that data, however, is orders of magnitude more difficult. Biopharma companies are under pressure from all sides to leverage the power of data analytics. Financial stakeholders expect a timely return on their investment. Regulators are closely scrutinizing the biopharma industry as it explores new...

Discover six key best practices that help medical monitors detect risks early in clinical trials by leveraging data-driven insights and proactive monitoring strategies.

This article discusses how Indian CROs are driving a new era in pharmaceutical R&D, leveraging AI, data-driven insights, and digital platforms to accelerate drug discovery, boost efficiency, and enable global collaboration.